Illumen Therapeutics

Business Services · Colorado, United States · 11-50 Employees

View Company Info for Free

Overview

Headquarters

4845 Pearl East Cir Ste 118, Boulder, Co...

Revenue

<$5 Million

Industry

Business Services Research & Development
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1

About Illumen Therapeutics

Illumen Therapeutics is focused on developing innovative treatments for aggressive cancers through PARN inhibitor drugs that enhance functional p53 levels. By targeting the common dysregulation of p53, a vital tumor suppressor, the company aims to revolutionize cancer therapy. Currently in the hit-to-lead stage, Illumen is leveraging pioneering research from the University of Colorado Boulder's BioFrontiers Institute. As a spin-out from the university, Illumen Therapeutics is poised to make significant contributions to cancer treatment.Explore more
Popular SearchesIllumen TherapeuticsSIC Code 87,873NAICS Code 54,541Show more

Illumen Therapeutics Org Chart

RB
United States flag for contact location.

Chief Executive Officer & Co-Founder

PhoneEmail

Is Illumen Therapeutics your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Illustration of an envelope

Top Business Services Companies

Frequently Asked Questions Regarding Illumen Therapeutics

What is Illumen Therapeutics's official website?
Illumen Therapeutics's official website is www.illumentx.com
What is Illumen Therapeutics's Revenue?
Illumen Therapeutics's revenue is <$5 Million
What is Illumen Therapeutics's SIC code?
Illumen Therapeutics's SIC: 87,873
What is Illumen Therapeutics's NAICS code?
Illumen Therapeutics's NAICS: 54,541
How many employees does Illumen Therapeutics have?
Illumen Therapeutics has 11-50 employees
What industry does Illumen Therapeutics belong to?
Illumen Therapeutics is in the industry of: Business Services, Research & Development
What does Illumen Therapeutics do?

Illumen Therapeutics is focused on developing innovative treatments for aggressive cancers through PARN inhibitor drugs that enhance functional p53 levels. By targeting the common dysregulation of p53, a vital tumor suppressor, the company aims to revolutionize cancer therapy. Currently in the hit-to-lead stage, Illumen is leveraging pioneering res... earch from the University of Colorado Boulder's BioFrontiers Institute. As a spin-out from the university, Illumen Therapeutics is poised to make significant contributions to cancer treatment.Read More

Is Illumen Therapeutics a public company?
Illumen Therapeutics is private company therefore does not currently have an official ticker symbol
See more information about Illumen Therapeutics

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.